Full Text View
Tabular View
No Study Results Posted
Related Studies
The Derivation of Human Embryonic Stem Cell Lines From PGD Embryos
This study is currently recruiting participants.
Verified by Hadassah Medical Organization, April 2009
First Received: July 16, 2006   Last Updated: May 5, 2009   History of Changes
Sponsored by: Hadassah Medical Organization
Information provided by: Hadassah Medical Organization
ClinicalTrials.gov Identifier: NCT00353210
  Purpose

Human embryonic stem cells (hESCs) are isolated from the early human embryo and have the capability to proliferate indefinitely in culture and to develop into nearly every cell of the human body. hESC are important for studying developmental biology and for cell replacement therapies for the treatment of degenerative human diseases. An additional use for embryonic stem cells would be for the in vitro study of diseases. hESC lines derived from embryos diagnosed as abnormal by PGD testing would afford such models for study. Because embryos tested by PGD and found to be abnormal would only under rare circumstances be transferred to the uterus of a woman (and in most cases would be discarded), the derivation of new hESC lines from these embryos would provide a viable less ethically-objectionable source of cells with which to study the mechanisms of differentiation and developmental biology.


Condition
Infertility

MedlinePlus related topics: Infertility
U.S. FDA Resources
Study Type: Observational
Official Title: The Derivation of Human Embryonic Stem Cell Lines From PGD Embryos

Further study details as provided by Hadassah Medical Organization:

Biospecimen Retention:   Samples With DNA

Biospecimen Description:

Retain serum samples of embryo donors.


Estimated Enrollment: 30
Study Start Date: April 2004
Estimated Study Completion Date: October 2009
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Embryo donors of embryos that have undergone PGD analysis after IVF which the donors have no intention of using for family-building purposes.

Criteria

Inclusion Criteria:

  • Couple has derived embryos by IVF.
  • Couple has tested these embryos by PGD and does not want to utilize the embryos to build their families.
  • Couple signs informed consent.

Exclusion Criteria:

  • Couple does not sign informed consent.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00353210

Contacts
Contact: Benjamin E. Reubinoff, M.D. PhD. 011-972-2-677-7111 ext 74569 reubinof@md.huji.ac.il
Contact: Shelly E. Tannenbaum, B.S. 011-972-2-677-7111 ext 77947 stannenbaum@hadassah.org.il

Locations
Israel
Hadassah Medical Organization Recruiting
Jerusalem, Israel, 91120
Contact: Arik Tzukert, DMD     011-972-2-677-7111 ext 76095     arik@hadassah.org.il    
Contact: Hadas Lemberg, PhD     011-972-2-677-7111 ext 77572     lhadas@hadassah.org.il    
Principal Investigator: Benjamin E. Reubinoff, M.D. PhD.            
Sponsors and Collaborators
Hadassah Medical Organization
Investigators
Principal Investigator: Benjamin E. Reubinoff, M.D. PhD. Hadassah Medical Organization
  More Information

Additional Information:
Publications:
Responsible Party: Hadassah Medical Organization ( Professor Benjamin Reubinoff )
Study ID Numbers: 24-23.04.04-HMO-CTIL
Study First Received: July 16, 2006
Last Updated: May 5, 2009
ClinicalTrials.gov Identifier: NCT00353210     History of Changes
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Hadassah Medical Organization:
IVF
embryos
research
donation
surplus
stem cells
abnormal embryo
screening

Study placed in the following topic categories:
Genital Diseases, Female
Infertility
Genital Diseases, Male

Additional relevant MeSH terms:
Genital Diseases, Female
Infertility
Genital Diseases, Male

ClinicalTrials.gov processed this record on May 07, 2009